Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Federal Medicaid Cuts
  • Generic Drugs
  • High-Deductible Plans
  • Gun Violence Trauma
  • Hospital Nutrition

WHAT'S NEW

  • Federal Medicaid Cuts
  • Generic Drugs
  • High-Deductible Plans
  • Gun Violence Trauma
  • Hospital Nutrition

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Aug 10 2022

Full Issue

Perspectives: SSRIs Don't Actually Balance Brain Chemicals; Pfizer Making Smart Acquisitions

Read recent commentaries about drug-cost issues.

Bloomberg: Pharma Overpromised On Antidepressants

The most popular depression drugs taken by millions don’t work by fixing an “imbalance of the brain's neurotransmitters,” as many drug advertisements claim or imply. (Faye Flam, 8/8)

Bloomberg: Pfizer Can Get Sickle-Cell Drugs To More Patients

Pfizer continues to spend its Covid windfall wisely. Today, the pharma company said it would spend $5.4 billion to buy Global Blood Therapeutics, which has one approved drug to treat sickle-cell disease and two more in development. (Lisa Jarvis, 8/8)

Also —

Stat: The Drug Pricing Bill, An Inevitable Solution, Will Have Unintended Results

There’s really no ignoring the inexorable math that led the Senate to approve a plan that will give Medicare unprecedented power to set the prices of some drugs. (Matthew Herper, 8/8)

The Washington Post: Drug Companies Are Warning That Medicare Pricing Reform Spells Doom. Don't Fall For It

Democrats are on the verge of passing legislation that, among other things, would empower the government to directly negotiate the price Medicare pays for a handful of the costliest prescription drugs. The measure has precipitated hyperbole from industry lobbyists, who say it represents an existential threat to medical innovation. (Avik Roy and Gregg Girvan, 8/8)

Los Angeles Times: Solve The Insulin Pricing Problem By Getting Government Into The Business

Insulin, an essential drug for more than 8 million Americans, is currently priced so steeply that many diabetics are forced to skip or ration this life-preserving treatment. (Jon D. Michaels, 8/8)

Columbus Dispatch: Drug Pricing Reforms Needed To Lower Out-Of-Pocket Costs

Federal lawmakers are at the plate again, ready to take a swing at prescription drug prices. Finding a way to lower drug costs for consumers is commendable and necessary. However, the current Senate Budget Reconciliation Bill will miss an opportunity to knock one out of the park. (Luke Russell, 8/3)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF